Skip to main content
. 2016 Nov 1;6(11):2532–2546.

Table 1.

Relative inhibition of pancreatic cancer and normal cell viabilities by the PCAIs and compared to current therapies

EC50 (µM)

MIAPaCa-2 Panc-1 BxPC-3 HPAF-II HEK-293
NSL-BA-036 4.4 2.6 3.3 15 26
NSL-BA-040 3.4 1.8 2.4 9.9 8
NSL-BA-055 2.4 1.9 2.0 2.1 > 50
NSL-BA-056 5.1 3.3 7.3 11 24
Erlotinib > 50 ND ND > 50 ND
Gemcitabine > 50 ND ND > 50 ND